Kala Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KALA)

$14.84 +0.07 (+0.47 %)
(As of 02/21/2018 07:48 AM ET)
Previous Close$14.77
Today's Range$14.67 - $15.02
52-Week Range$11.81 - $26.75
Volume149,800 shs
Average Volume475,853 shs
Market Capitalization$362.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals logoKala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Debt-to-Equity Ratio0.14%
Current Ratio11.00%
Quick Ratio11.00%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales9,096.92
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees25
Outstanding Shares24,520,000

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.14. View Kala Pharmaceuticals' Earnings History.

Where is Kala Pharmaceuticals' stock going? Where will Kala Pharmaceuticals' stock price be in 2018?

5 brokers have issued 1 year price objectives for Kala Pharmaceuticals' shares. Their predictions range from $19.00 to $46.00. On average, they anticipate Kala Pharmaceuticals' share price to reach $35.80 in the next year. View Analyst Ratings for Kala Pharmaceuticals.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a increase in short interest during the month of January. As of January 12th, there was short interest totalling 1,913,480 shares, an increase of 62.0% from the December 29th total of 1,181,331 shares. Based on an average trading volume of 760,981 shares, the days-to-cover ratio is currently 2.5 days. Currently, 13.2% of the shares of the company are sold short.

Who are some of Kala Pharmaceuticals' key competitors?

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the folowing people:

  • Mark T. Iwicki, Chairman of the Board, President, Chief Executive Officer (Age 50)
  • Mary Reumuth CPA, Chief Financial Officer, Treasurer (Age 42)
  • Todd M. Bazemore, Chief Operating Officer (Age 47)
  • Vincent Kosewski, Senior Vice President - Manufacturing and Supply Chain Management (Age 54)
  • Michele LaRussa, Senior Vice President - Regulatory Affairs and Quality Assurance (Age 47)
  • Hongming Chen, Chief Scientific Officer (Age 46)
  • Kim Brazzell Ph.D., Chief Medical Officer (Age 64)
  • Gregory Grunberg M.D., Independent Director (Age 44)
  • Paulina Hill Ph.D., Independent Director (Age 35)
  • Andrew Ian Koven, Independent Director (Age 58)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

When did the company's lock-up period expire?

Kala Pharmaceuticals' lock-up period expired on Tuesday, January 16th. Kala Pharmaceuticals had issued 6,000,000 shares in its public offering on July 20th. The total size of the offering was $90,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Who owns Kala Pharmaceuticals stock?

Kala Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include ORBIMED ADVISORS LLC (10.98%), BlackRock Inc. (3.01%), Victory Capital Management Inc. (2.32%), Wells Fargo & Company MN (1.17%), Farallon Capital Management LLC (0.75%) and Millennium Management LLC (0.42%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.

Who sold Kala Pharmaceuticals stock? Who is selling Kala Pharmaceuticals stock?

Kala Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc.. View Insider Buying and Selling for Kala Pharmaceuticals.

Who bought Kala Pharmaceuticals stock? Who is buying Kala Pharmaceuticals stock?

Kala Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Sphera Funds Management LTD., Emory University, Farallon Capital Management LLC, Millennium Management LLC, ING Groep NV and Wedbush Securities Inc.. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.

How do I buy Kala Pharmaceuticals stock?

Shares of Kala Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of Kala Pharmaceuticals stock can currently be purchased for approximately $14.84.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $362.18 million and generates $40,000.00 in revenue each year. Kala Pharmaceuticals employs 25 workers across the globe.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (KALA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kala Pharmaceuticals (NASDAQ:KALA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.80$36.80$36.80$36.80
Price Target Upside: 139.95% upside112.35% upside96.79% upside71.24% upside

Kala Pharmaceuticals (NASDAQ:KALA) Consensus Price Target History

Price Target History for Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals (NASDAQ:KALA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2018Wells Fargo & CoReiterated RatingOutperform -> Outperform$24.00 -> $19.00MediumView Rating Details
12/22/2017WedbushReiterated RatingOutperform$46.00MediumView Rating Details
11/19/2017JPMorgan Chase & Co.Set Price TargetBuy$35.00N/AView Rating Details
8/15/2017OppenheimerInitiated CoverageOutperform -> Outperform$46.00 -> $46.00LowView Rating Details
8/14/2017Bank of AmericaInitiated CoverageBuy -> Buy$33.00HighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Kala Pharmaceuticals (NASDAQ:KALA) Earnings History and Estimates Chart

Earnings by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals (NASDAQ KALA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.43)($0.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Kala Pharmaceuticals (NASDAQ:KALA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.22 EPS
Next Year EPS Consensus Estimate: $-1.93 EPS

Dividends

Dividend History for Kala Pharmaceuticals (NASDAQ:KALA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Kala Pharmaceuticals (NASDAQ KALA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 70.82%
Insider Trades by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)
Institutional Ownership by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals (NASDAQ KALA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2018Orbimed Advisors LlcMajor ShareholderBuy25,000$12.93$323,250.00View SEC Filing  
2/1/2018Orbimed Advisors LlcMajor ShareholderBuy362,240$15.00$5,433,600.00View SEC Filing  
1/29/2018Orbimed Advisors LlcMajor ShareholderBuy72,760$14.97$1,089,217.20View SEC Filing  
1/26/2018Orbimed Advisors LlcMajor ShareholderBuy22,760$14.93$339,806.80View SEC Filing  
1/24/2018Orbimed Advisors LlcMajor ShareholderBuy64,637$14.91$963,737.67View SEC Filing  
1/22/2018Orbimed Advisors LlcMajor ShareholderBuy75,000$14.98$1,123,500.00View SEC Filing  
1/19/2018Orbimed Advisors LlcMajor ShareholderBuy74,931$14.95$1,120,218.45View SEC Filing  
1/12/2018Orbimed Advisors LlcMajor ShareholderBuy240,484$13.28$3,193,627.52View SEC Filing  
1/10/2018Orbimed Advisors LlcMajor ShareholderBuy170,338$12.83$2,185,436.54View SEC Filing  
7/25/2017Longitude Capital Partners Ii,Major ShareholderBuy215,000$15.00$3,225,000.00View SEC Filing  
7/25/2017Orbimed Advisors LlcInsiderBuy319,333$15.00$4,789,995.00View SEC Filing  
7/25/2017Rajeev M ShahDirectorBuy533,333$15.00$7,999,995.00View SEC Filing  
7/20/2017Associates L.L.C. CdkMajor ShareholderBuy215,000$15.00$3,225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kala Pharmaceuticals (NASDAQ KALA) News Headlines

Source:
DateHeadline
Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by BrokeragesKala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 19 at 1:46 AM
Kala Pharmaceuticals (KALA) Stock Rating Upgraded by BidaskClubKala Pharmaceuticals (KALA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 17 at 2:10 PM
Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of StockInsider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of Stock
www.americanbankingnews.com - February 12 at 6:30 PM
Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per ShareZacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per Share
www.americanbankingnews.com - February 12 at 3:16 AM
Kala Pharmaceuticals (KALA) Downgraded by BidaskClub to "Sell"Kala Pharmaceuticals (KALA) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 11 at 9:42 PM
Analyzing Kala Pharmaceuticals (KALA) and Summit Therapeutics (SMMT)Analyzing Kala Pharmaceuticals (KALA) and Summit Therapeutics (SMMT)
www.americanbankingnews.com - February 4 at 11:08 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires $5,433,600.00 in StockKala Pharmaceuticals Inc (KALA) Major Shareholder Acquires $5,433,600.00 in Stock
www.americanbankingnews.com - February 2 at 6:16 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $339,806.80 in StockKala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $339,806.80 in Stock
www.americanbankingnews.com - January 30 at 6:32 PM
Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires 72,760 Shares of StockInsider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Acquires 72,760 Shares of Stock
www.americanbankingnews.com - January 30 at 6:14 PM
Kala Pharmaceuticals Inc (KALA) Sees Significant Growth in Short InterestKala Pharmaceuticals Inc (KALA) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 28 at 2:34 AM
Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per ShareKala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - January 26 at 5:04 AM
Kala Pharmaceuticals (KALA) Earns Outperform Rating from Wells Fargo & CoKala Pharmaceuticals (KALA) Earns Outperform Rating from Wells Fargo & Co
www.americanbankingnews.com - January 26 at 12:22 AM
Kala Pharmaceuticals Inc (KALA) Receives Consensus Rating of "Buy" from AnalystsKala Pharmaceuticals Inc (KALA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 25 at 1:40 AM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Buys 64,637 SharesKala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Buys 64,637 Shares
www.americanbankingnews.com - January 24 at 9:08 PM
Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys 74,931 Shares of StockInsider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Buys 74,931 Shares of Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $1,123,500.00 in StockKala Pharmaceuticals Inc (KALA) Major Shareholder Purchases $1,123,500.00 in Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Kala Pharmaceuticals Inc (KALA) Short Interest Up 28.5% in DecemberKala Pharmaceuticals Inc (KALA) Short Interest Up 28.5% in December
www.americanbankingnews.com - January 14 at 2:32 AM
Kala Pharmaceuticals (KALA) Rating Increased to Hold at BidaskClubKala Pharmaceuticals (KALA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - January 13 at 3:26 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 240,484 SharesKala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 240,484 Shares
www.americanbankingnews.com - January 12 at 6:26 PM
Kala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 170,338 SharesKala Pharmaceuticals Inc (KALA) Major Shareholder Orbimed Advisors Llc Purchases 170,338 Shares
www.americanbankingnews.com - January 12 at 6:26 PM
BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala PharmaceuticalsBRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
www.reuters.com - January 12 at 5:38 PM
Kala Pharmaceuticals Incs (KALA) Lock-Up Period To Expire  on January 16thKala Pharmaceuticals Inc's (KALA) Lock-Up Period To Expire on January 16th
www.americanbankingnews.com - January 9 at 1:22 AM
Kala Pharmaceuticals (KALA) Reports Mixed Results from Two Phase 3 Trials of KPI-121 0.25% in Dry Eye DiseaseKala Pharmaceuticals (KALA) Reports Mixed Results from Two Phase 3 Trials of KPI-121 0.25% in Dry Eye Disease
www.streetinsider.com - January 5 at 5:34 PM
Kala Pharma shares fall on mixed results from dry eye drug trialsKala Pharma shares fall on mixed results from dry eye drug trials
www.nasdaq.com - January 5 at 5:34 PM
UPDATE: Kala shares decline 8% on late-stage trial results for dry eye therapyUPDATE: Kala shares decline 8% on late-stage trial results for dry eye therapy
www.marketwatch.com - January 5 at 5:34 PM
Here's Why Kala Pharmaceuticals Got Crushed on FridayHere's Why Kala Pharmaceuticals Got Crushed on Friday
finance.yahoo.com - January 5 at 5:34 PM
Kala Pharmaceuticals (KALA) Buy Rating Reiterated at Wells Fargo & CoKala Pharmaceuticals' (KALA) Buy Rating Reiterated at Wells Fargo & Co
www.americanbankingnews.com - January 5 at 12:03 PM
Kala shares decline on late-stage trial results for dry eye therapyKala shares decline on late-stage trial results for dry eye therapy
finance.yahoo.com - January 5 at 9:02 AM
Kala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Hold" by AnalystsKala Pharmaceuticals Inc (KALA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 31 at 1:58 AM
Kala Pharmaceuticals (KALA) Upgraded to Sell at BidaskClubKala Pharmaceuticals (KALA) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - December 29 at 10:08 AM
Wedbush Reiterates Outperform Rating for Kala Pharmaceuticals (KALA)Wedbush Reiterates Outperform Rating for Kala Pharmaceuticals (KALA)
www.americanbankingnews.com - December 22 at 4:42 PM
Kala Pharmaceuticals Inc (KALA) Short Interest Up 34.1% in NovemberKala Pharmaceuticals Inc (KALA) Short Interest Up 34.1% in November
www.americanbankingnews.com - December 15 at 3:08 AM
Kala Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.72) Per Share (KALA)Kala Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.72) Per Share (KALA)
www.americanbankingnews.com - December 8 at 6:44 AM
Wedbush Comments on Kala Pharmaceuticals Incs FY2020 Earnings (KALA)Wedbush Comments on Kala Pharmaceuticals Inc's FY2020 Earnings (KALA)
www.americanbankingnews.com - December 7 at 12:52 AM
Kala Pharmaceuticals Inc (KALA) Given Average Recommendation of "Buy" by AnalystsKala Pharmaceuticals Inc (KALA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 6 at 1:46 AM
Comparing Kala Pharmaceuticals (KALA) and CTI BioPharma (CTIC)Comparing Kala Pharmaceuticals (KALA) and CTI BioPharma (CTIC)
www.americanbankingnews.com - November 26 at 11:20 AM
Kala Pharmaceuticals, Inc. (KALA) Given a $35.00 Price Target at J P Morgan Chase & CoKala Pharmaceuticals, Inc. (KALA) Given a $35.00 Price Target at J P Morgan Chase & Co
www.americanbankingnews.com - November 20 at 10:24 AM
Head to Head Comparison: Kala Pharmaceuticals (KALA) vs. Its CompetitorsHead to Head Comparison: Kala Pharmaceuticals (KALA) vs. Its Competitors
www.americanbankingnews.com - November 18 at 11:14 AM
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating OfficerKala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
finance.yahoo.com - November 13 at 10:22 AM
Kala Pharmaceuticals, Inc. (KALA) Receives Consensus Rating of "Buy" from BrokeragesKala Pharmaceuticals, Inc. (KALA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 11 at 1:46 AM
Kala Pharmaceuticals, Inc. (KALA) Issues  Earnings ResultsKala Pharmaceuticals, Inc. (KALA) Issues Earnings Results
www.americanbankingnews.com - November 8 at 4:45 PM
Kala Pharma reports 3Q lossKala Pharma reports 3Q loss
finance.yahoo.com - November 8 at 11:19 AM
BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56
www.reuters.com - November 8 at 11:19 AM
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business UpdateKala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update
finance.yahoo.com - November 8 at 11:19 AM
[$$] Private Equity Analysts 2017 Women to Watch: Venture Capital[$$] Private Equity Analyst's 2017 Women to Watch: Venture Capital
finance.yahoo.com - October 30 at 11:58 PM
Kala Pharmaceuticals: A Hidden Gem In BiotechKala Pharmaceuticals: A Hidden Gem In Biotech
seekingalpha.com - October 27 at 12:20 AM
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)
finance.yahoo.com - October 26 at 3:50 PM
Wedbush Reaffirms "Outperform" Rating for Kala Pharmaceuticals, Inc. (KALA)Wedbush Reaffirms "Outperform" Rating for Kala Pharmaceuticals, Inc. (KALA)
www.americanbankingnews.com - October 19 at 4:28 PM
Kala Pharmaceuticals, Inc. (KALA) Given Consensus Rating of "Buy" by BrokeragesKala Pharmaceuticals, Inc. (KALA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 17 at 2:52 AM
Zacks: Kala Pharmaceuticals, Inc. (KALA) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Kala Pharmaceuticals, Inc. (KALA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - October 15 at 8:30 AM

SEC Filings

Kala Pharmaceuticals (NASDAQ:KALA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kala Pharmaceuticals (NASDAQ:KALA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kala Pharmaceuticals (NASDAQ KALA) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.